Credit: Shutterstock

Q3 snap­shot: The IPO mar­ket shows fresh signs of im­prove­ment, but the biotech crunch con­tin­ues to bite

The biotech IPO mar­ket crashed hard last year, but we’re see­ing the win­dow creak open in a steady up­ward trend in 2023 that bodes for bet­ter times — though it’s a long, long way from a boom.

Chris Doko­ma­ji­lar at Deal­For­ma is back crunch­ing the num­bers, and we’ll start with signs that biotechs are brush­ing the dust off their S-1s and go­ing back to the mar­ket in search of cash to grow their busi­ness­es.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.